<DOC>
	<DOCNO>NCT00967369</DOCNO>
	<brief_summary>The goal clinical research study learn bortezomib give combination ifosfamide , carboplatin , etoposide ( routine chemotherapy combination call ICE ) help control Hodgkin 's lymphoma well ICE give alone . The safety drug combination also study .</brief_summary>
	<brief_title>Bortezomib Plus ICE ( BICE ) Versus Standard ICE Patients With Relapsed/Refractory Classical Hodgkin Lymphoma</brief_title>
	<detailed_description>The Study Drugs : Ifosfamide design slow stop growth cancer cell . Carboplatin design interfere growth cancer cell stop cell division , may cause cell die . Etoposide design block cell growth . Bortezomib design block protein play role cell function growth , may cause cancer cell die . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 group : - If Group 1 , receive bortezomib ICE . - If Group 2 , receive ICE . If one first 20 patient enrol study , equal chance assign either group . If join study 20 patient enrol , high chance assign group show effective . Study Drug Administration : Every `` study cycle '' make 2 week . Cycles may need long allow recovery . You need stay hospital receiving study drug . If Group 1 , need hospital 5-7 day . If Group 2 , need hospital 4-6 day . You receive ifosfamide vein 24 hour Day 1 cycle . When begin receive ifosfamide , also begin receive mesna vein 36 hour . Mesna drug help protect bladder damage ifosfamide . You receive carboplatin vein 1 hour Day 1 cycle . You receive etoposide vein 2 hour day Days 1-3 cycle . You receive Neulasta ( pegfilgrastim ) needle skin Day 5 ( If Group 1 ) Day 4 ( Group 2 ) cycle . Pegfilgrastim drug help low white blood cell count return normal level . If Group 1 , also receive bortezomib vein 5 second Days 1 4 cycle . Study Visits : At study visit , ask drug may take side effect may experience . Within 3 day cycle , follow test procedure perform : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - You chest x-ray CT scan check status disease ( Cycle 1 ) . On day receive study drug , blood ( 2 teaspoon time ) drawn routine test . One ( 1 ) time week , blood ( 2 teaspoon ) draw routine test . On Day 21 ( +/- 7 day ) Cycle 3 , follow test procedure perform : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - You chest x-ray check status disease . - You CT scan neck , chest , abdomen , pelvis check status disease . - You PET/CT scan check status disease . - You bone marrow biopsy check status disease . If find eligible stem cell transplant visit , take study . Your doctor describe procedure sign separate consent form . Length Study : You receive study drug 6 cycle . You take study intolerable side effect disease get bad . End-of-Treatment Visit : After finish receiving study drug reason , end-of-treatment visit . At end-of-treatment visit , follow test procedure perform : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - You chest x-ray check status disease . - You CT scan neck , chest , abdomen , pelvis check status disease . - You PET/CT scan check status disease . - If doctor think need , bone marrow biopsy check status disease . Follow-Up Visits : After end-of-treatment visit , follow-up visit every 4 month 2 year . The following test procedure perform : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - You chest x-ray check status disease . - You CT scan neck , chest , abdomen , pelvis check status disease . This investigational study . Bortezomib FDA approve commercially available treatment mantle cell lymphoma myeloma . ICE FDA approve commercially available treatment several type lymphoma , include relapsed refractory Hodgkins lymphoma . The combination bortezomib ICE treatment Hodgkin 's lymphoma investigational . Up 50 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Relapsed refractory classical Hodgkin lymphoma 2 . Patients must receive frontline standard anthracycline contain regimen , ABVD , Stanford V , BEACOPP . 3 . Bidimensionally measurable disease least 1 lesion &gt; = 2.0 cm single dimension . 4 . Patients must meet follow require baseline laboratory data : ) absolute neutrophil count ( ANC ) &gt; = 1,500/microL , b ) platelet count &gt; = 100,000/ microL , c ) hemoglobin &gt; = 8 g/dL , ) serum bilirubin &lt; 2.0 mg/dL , e ) alkaline phosphatase &lt; 2 x upper limit normal ( ULN ) , f ) AST ALT &lt; 2 x ULN , g ) serum creatinine &lt; = 1.5 mg/dL . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . 6 . Age &gt; = 16 year . 7 . Females childbearing potential must negative serum betahCG pregnancy test must agree use 2 highly effective contraceptive method ( hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) study 3 month completion protocol treatment . Females nonchildbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy . 8 . Males partner childbearing potential must agree use effective contraceptive method study 3 month completion protocol treatment . 9 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 1 . Lymphocyte predominant Hodgkin lymphoma histology . 2 . More one prior chemotherapy regimen . 3 . Prior autologous allogeneic stem cell transplant . 4 . Presence CNS involvement Hodgkin lymphoma . 5 . Known HIV infection AIDS . 6 . Active Hepatitis B C infection history cirrhosis . 7 . Grade 2 great peripheral neuropathy within 14 day enrollment . 8 . Hypersensitivity boron mannitol . 9 . Prior bortezomib therapy . 10 . Another primary malignancy ( squamous cell basal cell carcinoma skin , situ carcinoma cervix , squamous intraepithelial lesion PAP smear , treated prostate cancer stable PSA ) patient diseasefree least 3 year . 11 . Patients congestive heart failure , Class III IV , New York Heart Association ( NYHA ) criterion . 12 . Patients myocardial infarction 6 month prior enrollment , uncontrolled angina , severe uncontrolled ventricular arrythmias , ECG evidence acute ischemia active conduction system abnormality . 13 . Patient medical psychiatric illness likely interfere participation clinical study . 14 . Female subject pregnant breastfeeding . 15 . Patient receive investigational drug within 14 day enrollment . 16 . Patients use concurrent therapy corticosteroid great equal 20 mg/day prednisone equivalent . 17 . Patients active systemic bacterial , viral , fungal infection require IV antimicrobial within 4 week prior protocol treatment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Classical Hodgkin Lymphoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>ICE</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>BICE</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
</DOC>